Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex
Diseases
Illumina, Inc. (NASDAQ:ILMN) and Bio-Rad Laboratories, Inc. (NYSE:BIO) (NYSE:BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive
solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to
investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170109006365/en/
Illumina® Bio-Rad® Single-Cell Sequencing Solution, including new ddSEQ Single-Cell Isolator (pictured with NextSeq
500) (Photo: Business Wire)
Single-cell analysis enables a deep view into the gene expression of individual cells to understand their functions in complex
tissues. The solution delivers high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly,
and time consuming process. Human development and disease research, fields in which single-cell sequencing is widely applicable, is
expected to benefit most from this new offering.
“Single-cell genomics provides the opportunity to look at stem cells turning into neurons that are lost in diseases like
Parkinson’s and amyotrophic lateral sclerosis (also known as Lou Gehrig’s disease) with much higher accuracy,” said Clive Svendsen,
PhD, Director, Cedars-Sinai Board of Governors Regenerative Medicine Institute in Los Angeles. His laboratory tested the
application of the new platform to profile single cells used in modeling neurodegenerative diseases.
“Using the solution made it possible to detect single cells in a population that was maturing faster than others, allowing us to
produce better models of disease,” added Ritchie Ho, PhD, Project Scientist in the Cedars-Sinai Board of Governors Regenerative
Medicine Institute and lead researcher for the testing.
The solution comprises the ddSEQ™ Single-Cell Isolator and SureCell™ WTA 3’ Library Prep Kit. Bio-Rad’s best-in-class droplet
partitioning technology, Droplet Digital™ technology, is used to isolate and barcode single cells for downstream sequencing on many
of Illumina’s leading NGS instruments. The comprehensive workflow solution includes primary and secondary data analysis conducted
via the BaseSpace® Informatics Suite, Illumina’s cloud-based genomics computing environment, and tertiary data analysis
and visualization with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry analysis.
“Through our close collaboration with Illumina we developed a seamless and scalable solution for single-cell analysis,” said
Annette Tumolo, Bio-Rad Executive Vice President and General Manager, Digital Biology Group. “We are proud to equip cell biologists
and others in the research community with the tools they need to power new discovery.”
“By offering cell biologists access to technologies that make single-cell analysis cost effective and easy to adopt, we hope to
enable scientists to advance complex disease research using gene expression insights,” said Rob Brainin, Vice President and General
Manager, Applied Genomics at Illumina. “Our collaboration with Bio-Rad has allowed us to bring this technology to market quickly
and empower our customers to unlock the power of the genome to improve human health.”
The Illumina® Bio-Rad® Single-Cell Sequencing Solution will begin shipping in early February. For more information about the
instruments, reagents, and workflow, visit www.bio-rad.com/ddSEQ.
For Research Use Only. Not for use in diagnostic procedures.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
To learn more, visit www.illumina.com and follow @illumina.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) (BIOb) develops, manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and
customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the
biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves
more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more
than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding
the launch of any products. Among the important factors that could cause actual results to differ materially from those in any
forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables and to deploy
new products, services, and applications, and expand the markets, for our technology platforms; (ii) our ability to manufacture
robust instrumentation and consumables; (iii) achievement and timing of the planned deconsolidation of GRAIL, Inc.’s financial
results in our financial statements; (iv) our ability to successfully identify and integrate acquired technologies, products, or
businesses; (v) our expectations and beliefs regarding future conduct and growth of the business and the markets in which we
operate; (vi) challenges inherent in developing, manufacturing, and launching new products and services; and (vii) the application
of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and
judgments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are
released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or
confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce
new products and the opportunities that may result from such new products. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,”
“continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements
contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from
those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and
market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality
and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of
the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com
or
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Gwen Gordon
858-882-6822
pr@illumina.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170109006365/en/